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When the Lord smote the
Philistines with emerods in their
secret parts he left it to historians
to debate the nature of this lethal
affliction. Literally translated,
emerods are haemorrhoids, but it
is surely unlikely that so hardy a
race would have succumbed to
an epidemic of piles. Scholarly
opinion seems to concur that the
emerods were buboes in the
groin, one of the agonising
manifestations of the plague. So
the disease, it seems, has been
with us for millenia, but since the
last major outbreak in 1894, which
carried off 12 million of its victims,
has – or so it was thought until a
few years ago – yielded to
antibiotics.
Now the Black Death, it seems,
has returned, and most recently in
antibiotic-resistant form. More, as
a past leader of the Soviet
biological weapons programme,
Colonel Kanatjan Alibekov (now
Ken Alibek and an American
citizen) has disclosed, strains
carrying plasmids for resistance
to a range of antibiotics, and for
good measure a gene expressing
a neurotoxin, were developed in
Russia and stockpiled in twenty-
ton quantities. Yersinia pestis,
Alibek averred, is easily
‘weaponized’, and pneumonic
plague, the most virulent form, is
conveniently disseminated on the
breath of expiring victims.
A more present threat is drug-
resistant tuberculosis, which is
beginning to ravage the
undernourished underclasses in
Russia and elsewhere, and has
become a familiar spectre in the
hospitals of the West. It is thought
to kill annually some 28 million
people around the world.
The theme of Shnayerson and
Plotkin’s scrupulously researched
and mesmerising book is the
infinite capacity of bacteria to
mutate and neutralise all missiles
that science has thrown at them,
and the human folly and rapacity
that has allowed them full scope.
The theme ... is the infinite
capacity of bacteria to
mutate and neutralise all
missiles that science has
thrown at them and the
human folly and rapacity
that has allowed them full
scope.
The miracle of penicillin did not
endure long: even before it
reached the market the
emergence of resistant strains of
Gram-positive pathogens had
been observed, and there were
already muted warnings of what
was to come. These did not
prevent the elixir from turning up
in cough medicines,
mouthwashes and soaps, and,
Michael Shnayerson and Mark
Plotkin tell us, it was even added
to soft drinks as a ‘general health
powder’. Such practices, at least,
ceased in the 1950s, but worse
was in store, with the introduction
of antibiotics into animal feeds as
‘growth promoters’. As drug
resistance became ever more
prevalent, chemists and
microbiologists made heroic
efforts to isolate new types of
antibiotics from samples of soil,
vegetation and sewage from
around the world. The microbes
fought off every one, and
‘complications after surgery’ was
a phrase that crept increasingly
into the obituary columns.
Doctors were at least persuaded
to reserve the most powerful that
remained to them, vancomycin,
as the ‘drug of last resort’, to be
used only when all else had failed.
But it was only a question of time
before vancomycin-resistant
bacteria began to appear in
animals, for in Europe a
sufficiently close analogue of
vancomycin, avoparcin, had come
into wide use as a growth
promoter.
Vancomycin-resistant
Enterococci were discovered in
1995 by researchers in a Danish
state laboratory. The Danes acted
quickly to eliminate avoparcin (as
the prescient Swedes had already
done nine years earlier). When the
EU embarked on its own
ponderous process of evaluation,
Roche, the manufacturers, fought
against the ban. If implemented,
they promised, it would bring
disaster to European agriculture,
the economy would wither and
farmers throughout the EU go
bankrupt.
Eventually – though not until
1998 – the worst, at least, of the
antibiotic growth-promoters
vanished from the European
scene, a move opposed by only
two countries, Belgium and the
UK. No farmers went bankrupt.
Meanwhile, in the US a
schoolteacher had tested the
waters of the Ohio River and
found a plethora of antibiotics,
including vancomycin, originating
presumably from inadequately
filtered hospital and domestic
effluents. European waters were
no better.
Science, to be sure, had moved
on: two classes of synthetic
compounds, unrelated to any
known natural products and
highly active against the most
dangerous Gram-positive
pathogens, had been discovered.
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These were the oxazolidinones
and a group of quinolone
derivatives. The oxazolidinones,
bacteriostatic rather than
bactericidal, were expensive: it
had cost Rhone-Poulenc Rorer
$0.5 billion to bring Synercid to
the market, and this outlay was
reflected in the cost of treatment
– up to $250 a day. It was agreed
that neither the oxazolidinones
nor the quinolones, licensed for
human use, would be given to
animals, but before long the
agricultural industry had got its
hands on analogues of both,
either for growth-enhancement or
for therapy.
Before long animals around the
world were found to be
abundantly infested with
pathogens, with Salmonella or
Campylobacter. (The egregious
UK agriculture minister, Edwina
Curry, lost her job for uttering the
unpalatable truth.)
In the US consumer groups and
the Center for Disease Control,
which had for years been
campaigning ceaselessly against
indiscriminate use of antibiotics,
demanded the withdrawal of
quinolones from agriculture. As
ever, the powerful agricultural
lobby lied and intrigued to protect
profits.
The story of the antibiotics is a
melancholy litany of folly and
greed. Human nature will not be
gainsaid. As Kipling has it,
There are only four things
certain since Social Progress
began –
That the Dog returns to his
vomit and the Sow returns to her
Mire,
And the burnt Fool’s bandaged
finger goes wabbling back to the
Fire …
Attempts to find new antibiotic
substances are not now, it
seems, a matter of high priority
for Big Pharma. The cost of
bringing drugs to market has
risen alarmingly, and it is
medication for chronic maladies,
rather than single-shot cures for
infections, that will sustain the
profits.
Tuberculosis is still to a large
extent a disease of destitute
populations, though that is
beginning to change. The focus,
Shnayerson and Plotkin reveal,
has in large measure shifted to
vaccines, assisted by genomic
strategies and improved
procedures for rapid identification
of the agents of infection. And
perhaps the whole notion of
eliminating the wily pathogens
once and for all was
misconceived: might it not be
better to treat infections
conservatively, for then the
evolutionary advantage will rest
with more benign strains, which
do not kill their hosts?
There is also now much
research on peptides to inhibit
the binding of the pathogen to its
cell receptors. These have been
sought in such improbable
hiding-places as the saliva of the
Komodo dragon. Finally, the long-
neglected possibilities of
bacteriophages are once more
being taken seriously.
It was a revelation to me that
these specialised viruses have
been in therapeutic use in the
countries of the former Soviet
imperium ever since their
discovery nearly a century ago, or
that they reputedly saved untold
numbers of lives on the
battlefields of the Second World
War. Research into phage therapy
has somehow continued in the
decayed and impoverished
laboratories of Eastern Europe,
most notably the Eliava Institute
in ravaged Tbilisi.
Perhaps, paradoxically, it is the
shadow of Al Qaeda and those
elusive envelopes of anthrax
bacilli that will now liberate the
money and talent needed to
combat the depredations of
man’s ancient unicellular
enemies.
All this and more you will learn
from The Killers Within, which
serves at once as a wholly
absorbing tale of scientific
detection, a lesson in biology, a
tableau of grand guignol and a
powerful admonition on the
misuse of science. Read, learn
and ponder.
Walter Gratzer is at the Randall Centre
for Molecular Mechanisms in Cell
Biology, King’s College, New Hunt’s
House, Guy’s Campus, St Thomas
Street, London SE1 1UL, UK.
Quick guide
Polycomb group
proteins
Jeffrey A. Simon
What are they? Polycomb group
(PcG) proteins are a set of general
transcriptional repressors
essential for development in many
organisms. They are best known
as repressors that restrict Hox
gene expression along the
anterior–posterior animal body
axis. About 15 PcG repressors
have been identified. They are
generally not related by shared
domains or structural motifs, but
form a family based on common
function.
Why are they important? PcG
proteins organize target gene
chromatin to maintain repressed
states for long periods of time and
through many cell divisions. So
they provide an important way to
keep genes shut off during
development or through
successive life stages. This type
of epigenetic phenomenon has
been called transcriptional or
chromatin memory.
Where does the name come
from? When PcG proteins are
disrupted in Drosophila, Hox
genes are derepressed in specific
body regions. For example, Hox
proteins normally restricted to the
abdomen become expressed
ectopically in the head and thorax.
This transforms body segments to
a more posterior character. In the
extreme case, all segments mimic
the hindmost abdominal segment,
which produces a developmental
dead end! Weak PcG mutations
often make the second and third
pairs of legs develop like the first
pair. Normally, the first pair of
male legs are uniquely decorated
with a bristly structure called the
sex comb, used for hugging
females. So weak PcG mutants
have extra sex combs, sometimes
on all six legs (and are
presumably better huggers).
Hence the name Polycomb.
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